Search Results

You are looking at 11 - 20 of 62 items for :

  • "peptide receptor radionuclide therapy (PRRT)" x
  • Refine by Access: All content x
Clear All
Free access

Dik J Kwekkeboom, Boen L Kam, Martijn van Essen, Jaap J M Teunissen, Casper H J van Eijck, Roelf Valkema, Marion de Jong, Wouter W de Herder, and Eric P Krenning

, the follow-up of patients with known disease, and lastly the selection of patients with inoperable and/or metastatic tumors for peptide receptor radionuclide therapy (PRRT). Newer ligands for SRI 99m Tc-Depreotide (Neotect, Diatide, Londonderry

Free access

Julie Refardt, Wouter T Zandee, Tessa Brabander, Richard A Feelders, Gaston J H Franssen, Leo J Hofland, Emanuel Christ, Wouter W de Herder, and Johannes Hofland

staging NETs ( Sundin et al. 2017 ). Furthermore, treatment with unlabelled somatostatin analogs (SSAs) or radiolabelled SSAs as in peptide receptor radionuclide therapy (PRRT) has shown prolongation of progression-free survival (PFS) in metastatic NET

Restricted access

M. C.f. Mulders, Q.g. de Lussanet de la Sablonière, M.l.f. Van Velthuysen, E.m. Roes, J Hofland, and Wouter W de Herder

Neuroendocrine ovarian metastases (NOM) predominantly derive from midgut neuroendocrine tumors (NETs) and develop in about 25% of women with advanced stage of this malignancy. Little is known of the growth rate and treatment response of NOM. We therefore evaluated the efficacy of different management options for patients with NOM, including peptide receptor radionuclide therapy (PRRT), somatostatin analogues (SSAs) and oophorectomy. Records were screened for patients with well-differentiated NOM of midgut origin that presented in our NET referral center between 1991 and 2022. Progression free survival (PFS) and tumor growth rate (TGR) of ovarian and extra-ovarian metastases were determined using RECIST 1.1. In 12 available patients undergoing PRRT, NOM were associated with a shorter PFS than extra-ovarian metastases (p=0.003). While PRRT induced a similar decrease in TGR for ovarian and extra-ovarian lesions in 9 patients with available data (-2.3 vs -1.4, p<0.05), only the TGR of NOM remained positive after PRRT. In 16 patients treated with SSAs, the TGR of NOM was almost three times that of extra-ovarian lesions during treatment (2.2 vs 0.8, p=0.011). Oophorectomy was performed in 46 of the 61 included patients and was significantly associated with a prolonged OS (115 vs 38 months, p<0.001). This association persisted after propensity score matching and correction for tumor grade and simultaneous tumor debulking. NOM have a higher TGR compared to extra-ovarian metastases, resulting in a shorter PFS after PRRT. Bilateral salpingo-oophorectomy should be considered for postmenopausal women with NOM undergoing surgery for metastatic midgut NETs.

Free access

Luohai Chen, Gopinath Gnanasegaran, Dalvinder Mandair, Christos Toumpanakis, Martyn Caplin, and Shaunak Navalkissoor

Introduction 177 Lutetium-DOTA 0 -Tyr 3 -octreotate ( 177 Lu-Dotatate) is a peptide receptor radionuclide therapy (PRRT) licensed for treatment in patients with advanced well-differentiated gastroenteropancreatic neuroendocrine tumours (NET

Free access

Kjell Oberg

al . 2005 ). The tracer is also generated by a generator that makes it cheaper than traditional PET tracers developed by a cyclotron. Peptide receptors radionuclide therapy (PRRT) is a promising new tool in the management of patients with inoperable

Free access

Kimberly Kamp, Brenda Gumz, Richard A Feelders, Dik J Kwekkeboom, Gregory Kaltsas, Frederico P Costa, and Wouter W de Herder

progression, peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogs has been shown to be effective regarding tumor control ( Bergsma et al . 2012 ). Although 177 Lu-octreotate is being increasingly used, there are limitations to

Free access

Satya Das, Liping Du, Aimee Schad, Shikha Jain, Aaron Jessop, Chirayu Shah, David Eisner, Dana Cardin, Kristen Ciombor, Laura Goff, Marques Bradshaw, Dominique Delbeke, Martin Sandler, and Jordan Berlin

Introduction Peptide receptor radionuclide therapy (PRRT) has been a transformative therapy for patients with progressive well-differentiated neuroendocrine tumors (NETs). Though PRRT has been utilized in Europe since the mid-1990’s for

Free access

Bertrand Brieau, Olivia Hentic, Rachida Lebtahi, Maxime Palazzo, Makrem Ben Reguiga, Vinciane Rebours, Frederique Maire, Pascal Hammel, Philippe Ruszniewski, and Pierre Fenaux

, chemotherapies, and radiological and radionuclide therapies. Peptide receptor radionuclide therapy (PRRT) is a modern therapeutic approach using radionuclide combined with somatostatin analog peptide whose affinity with somatostatin receptors (SSRs) allows

Free access

Frédéric Castinetti, Alexander Kroiss, Rakesh Kumar, Karel Pacak, and David Taieb

approaches need to be developed in order to improve treatment planning in a given patient ( Sudbrock et al . 2010 , Sanchez-Crespo 2013 ). Peptide receptor radionuclide therapy (PRRT) is an established treatment option for well-differentiated and advanced

Free access

Karel Pacak, Mark Kidd, Leah Meuter, and Irvin M Modlin

prior treatment. Fifty-three patients underwent several therapies. Overall, 50 (70%) had surgery, 16 received radiation, 8 received cold somatostatin analogs, 9 received chemotherapy, 2 received peptide receptor radionuclide therapy (PRRT), 2 underwent